Skip to main content
. 2021 Feb 1;10:572203. doi: 10.3389/fonc.2020.572203

Table 3.

Subgroup analysis on the outcome of PFS.

Comparison Studies HR(95%CI) Pz-value I2 PH-value
Region Asian 16 1.30(0.86,1.97) 0.209 75.8 0.000
Non-Asian 10 1.04(1.00,1.07) 0.040 0.0 0.670
Sample size <100 16 0.98(0.72,1.34) 0.921 70.4 0.000
>100 10 1.14(0.83,1.56) 0.423 50.4 0.033
IHC counting method SI 8 1.22(0.73,2.05) 0.451 77.3 0.000
SP 15 0.89(0.74,1.08) 0.226 0.0 0.478
IRS 3 2.22(0.75,6.53) 0.149 87.7 0.000
Cut-off
values
1% 8 0.75(0.55,1.02) 0.065 0.0 0.669
5% 2 0.76(0.43,1.36) 0.361 0.0 0.947
Others 16 1.25(0.94,1.65) 0.120 74.4 0.000
Cancer type Ovarian 10 1.14(0.87,1.49) 0.360 62.0 0.005
Cervical 9 0.87(0.54,1.39) 0.561 68.6 0.001
Endometrial 7 1.27(0.70,2.30) 0.431 56.1 0.034
Antibody type Monoclonal 22 0.95(0.73,1.22) 0.665 52.1 0.002
Unclear 4 1.65(0.90,3.01) 0.106 86.3 0.000
Antibody source Mouse 3 0.79(0.26,2.41) 0.684 85.7 0.001
Rabbit 19 0.99(0.79,1.24) 0.894 28.5 0.120
Unclear 4 1.65(0.90,3.01) 0.106 86.3 0.000
IHC detection area Tumor cells 17 1.16(0.86,1.56) 0.337 59.8 0.001
TICs 7 1.05(0.68,1.61) 0.830 54.4 0.041
Tumor cells + TICs 2 0.60(0.29,1.24) 0.167 75.7 0.043
HR method MV 7 1.46(0.82,2.62) 0.201 68.4 0.004
UV 19 0.95(0.76,1.20) 0.661 62.3 0.000
HR source Reported 16 1.29(1.00,1.67) 0.052 67.1 0.000
Estimated 10 0.65(0.50,0.84) 0.001 3.3 0.409

OS, overall survival; UV, univariate analysis; MV, multivariate analysis; SP, staining percentage; SI, staining intensity score; IRS, immunoreactive SI (that is, IRS = SI × SP); HR, hazard ratio; CI, confidence interval; IHC, immunohistochemistry; TIC, tumor-infiltrating immune cells. PZ, p-value for association; PH, p-value for heterogeneity obtained by Q-test; I2, the degree of heterogeneity by I2 statistic. Bold indicated the significance after analysis of two or more than two studies (p < 0.05).